See more : Headwater Exploration Inc. (HWX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Chardan Healthcare Acquisition 2 Corp. (CHAQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chardan Healthcare Acquisition 2 Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Argentum 47, Inc. (ARGQ) Income Statement Analysis – Financial Results
- Evelo Biosciences, Inc. (EVLO) Income Statement Analysis – Financial Results
- Kanematsu Engineering Co., Ltd. (6402.T) Income Statement Analysis – Financial Results
- co.don AG (CNWK.DE) Income Statement Analysis – Financial Results
- Agile Group Holdings Limited (AGPYF) Income Statement Analysis – Financial Results
Chardan Healthcare Acquisition 2 Corp. (CHAQ)
About Chardan Healthcare Acquisition 2 Corp.
Chardan Healthcare Acquisition 2 Corp. intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was founded in 2018 and is based in New York, New York.
Unable to fetch income statement for: CHAQ
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders...
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D.,...
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance
Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - CHAQ
NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State...
U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week
Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the brakes as we near the election, with just one new IPO filing.
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week
September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings.
Kamada Ltd. (KMDA) Q2 2019 Earnings Call Transcript | The Motley Fool
KMDA earnings call for the period ending June 30, 2019.
Source: https://incomestatements.info
Category: Stock Reports